Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting now · Not applicable

Conditions studied: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

In brief

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Key facts

Study ID

NCT05237258

Run by

Massachusetts General Hospital

People needed

2300

Starts

2022-06-01

Expected to finish

2029-04-01

Last updated by the study team

2025-07-25

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient Inclusion Criteria
• Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
• Patients with new diagnosis ≥ 60 years of age
• An antecedent hematologic disorder
• Therapy related-disease
• Relapsed or primary refractory AML
• Within five business days of initiating therapy with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.
• Caregiver Inclusion Criteria
• Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.

You may not qualify if…

• Patient Exclusion Criteria
• Patients with a diagnosis of acute promyelocytic leukemia (APML)
• Patients with AML receiving supportive care alone
• Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
• Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment
• Patients expected to be discharged within 2 days

Where it is running

• University of Alabama - Birmingham — Birmingham, Alabama, United States (enrolling)
• Stanford University — Stanford, California, United States (enrolling)
• University of Colorado Denver I Anschutz Medical Campus — Denver, Colorado, United States (enrolling)
• University of Miami — Miami, Florida, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Emory University — Atlanta, Georgia, United States (enrolling)
• Northwestern University — Evanston, Illinois, United States (enrolling)
• Indiana University — Bloomington, Indiana, United States (enrolling)
• Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• University of Rochester — Rochester, New York, United States (enrolling)
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• Duke University — Durham, North Carolina, United States (enrolling)
• Ohio State University — Columbus, Ohio, United States (enrolling)
• Oregon Health & Science University — Portland, Oregon, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
• University of Wisconsin — Madison, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.